13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
Become familiarised with pharmacodynamic drug interactions, get comprehensively informed about in vitro and vivo aspects of the ICH M12 drug interaction guidelines, build up knowledge on biomarkets for detecting clinical DDIs and hear the latest update on FDA scientific efforts.
Dr Jorg Taubel, CEO ofRichmond Pharmacology will be attending.
Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology
December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
